NextCure (MUN:2US) - Hisse Senedi Fiyatı, Haberler ve Analizler

2US Stoklara Genel Bakış

A clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Daha fazla detay

2US temel anali̇z
Kar Tanesi Skoru
Değerleme	2/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	0/6
Finansal Sağlık	6/6
Temettüler	0/6

Risk Analizi

Hisse senetleri oldukça likit değildir

Önümüzdeki 3 yıl boyunca kazançların yılda ortalama 2.6% oranında düşmesi öngörülüyor

Geliri 1 milyon ABD dolarından az ( $0 )

Anlamlı bir piyasa değeri yok ( €45M )

+ 1 daha fazla risk

NextCure, Inc. Rakipler

4SC

DB:VSC

€51.9m

2invest

XTRA:2INV

€62.7m

Medigene

XTRA:MDG1

€17.4m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti NextCure
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	US$1.37
52 Haftanın En Yüksek Seviyesi	US$1.47
52 Haftanın En Düşük Seviyesi	US$1.11
Beta	0.67
11 Aylık Değişim	0%
3 Aylık Değişim	8.57%
1 Yıllık Değişim	n/a
33 Yıllık Değişim	-77.99%
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-92.59%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	2US	DE Biotechs	DE Pazar
7D	0%	0.8%	0.8%
1Y	n/a	-18.3%	8.6%

Getiri vs. Endüstri: 2US un German Biotechs sektörüne göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Getiri vs Piyasa: 2US un German Piyasasına göre nasıl performans gösterdiğini belirlemek için yeterli veri yok.

Fiyat Oynaklığı

Is 2US's price volatile compared to industry and market?
2US volatility
2US Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.5%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

İstikrarlı Hisse Senedi Fiyatı: 2US son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 2US 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
2015	82	Michael Richman	www.nextcure.com

NextCure, Inc. Temel Bilgiler Özeti

NextCure'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
2US temel i̇stati̇sti̇kler
Piyasa değeri	€41.33m
Kazançlar(TTM)	-€58.86m
Gelir(TTM)	n/a

0.0x

P/S Oranı

-0.7x

F/K Oranı

2US aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
2US gelir tablosu (TTM)
Gelir	US$0
Gelir Maliyeti	US$0
Brüt Kâr	US$0
Diğer Giderler	US$63.73m
Kazançlar	-US$63.73m

Son Raporlanan Kazançlar

Mar 31, 2024

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	-2.28
Brüt Marj	0.00%
Net Kâr Marjı	0.00%
Borç/Özkaynak Oranı	0%

2US uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

2US Stoklara Genel Bakış

Risk Analizi

NextCure, Inc. Rakipler

DB:VSC

€51.9m

XTRA:2INV

€62.7m

XTRA:MDG1

€17.4m

XTRA:HPHA

€105.8m

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

Recent updates

NextCure, Inc. Announces the Presentation of Preclinical Data Demonstrating That Treatment with Nc605, A Novel Anti-Siglec-15 (S15) Antibody

NextCure, Inc. Reports Preclinical Data for LNCB74 and Additional Clinical Biomarker Data for NC410 Combo At Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Presents Phase 1b Data on NC410 and Pembrolizumab Combination at ASCO 2024

New major risk - Revenue and earnings growth

NextCure, Inc., Annual General Meeting, Jun 20, 2024

NextCure, Inc. and LigaChem Biosciences, Inc. Present Preclinical Data on B7-H4 Antibody Drug Conjugate At AACR 2024

NextCure, Inc. Appoints Rakesh Dixit to Scientific Advisory Board

New major risk - Revenue and earnings growth

New major risk - Revenue and earnings growth

NextCure Presents Preclinical Data on a Novel Therapeutic Candidate Targeting VSTM-1 for the Treatment of Progressive Inflammatory Airway Disorders

Nextcure, Inc. Publishes Non-Clinical Data Demonstrating Anti-Siglec-15 Treatment Prevented Bone Loss Due to Immobilization from Acute Spinal Cord Injury

Nextcure, Inc. Provides Year-End Clinical Pipeline Updates

NextCure, Inc. Publishes Non-Clinical Data Defining the Mechanism of Action for NC525, a Novel LAIR-1 Antibody for AML

NextCure, Inc. Announces Presentation of New Preclinical Data Demonstrate Treatment with NC605

NextCure, Inc. Presents Preclinical Data on Nc181, A Novel Therapeutic Candidate Targeting Apoe4, for the Treatment of Alzheimer's Disease

NextCure, Inc. Announces Resignation of Garry A. Nicholson as from the Board of Directors

NextCure Presents Initial Data from Clinical Trial of NC762 and a Trial in Progress Poster for NC410 Combo at the 2022 Society for Immunotherapy of Cancer Annual Meeting

NextCure, Inc. Appoints Lisa M. Coussens to Scientific Advisory Board

NextCure, Inc. Announces Initiation of Phase 1b/2 Clinical Trial to Evaluate NC410 in Combination with KEYTRUDA (Pembrolizumab) in Patients with Immune Checkpoint Refractory or Naïve Solid Tumors

NextCure, Inc. Presents NC410 Data at the Extracellular Matrix Pharmacology Congress in Europe on Overcoming Clinical Limitations to Immunotherapy Through Remodeling Tumor ECM

Nextcure, Inc. Appoints Dr. Segal to Its Scientific Advisory Board

NextCure, Inc., Annual General Meeting, Jun 23, 2022

NextCure and the National Cancer Institute Announce Preclinical Data in Journal of Clinical Investigation

High number of new directors

High number of new directors

NextCure, Inc. and Collaborators Provide Data on Targets in Development at American Society of Hematology Annual Meeting

High number of new directors

Independent Director Xiaoxing Xu has left the company

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell 2500 Growth Index

Nextcure and Collaborators Publish Preclinical Data on Novel Immunomedicine Nc410

Independent Director has left the company

Full year 2020 earnings released: US$1.33 loss per share (vs US$2.15 loss in FY 2019)

Revenue misses expectations

NextCure, Inc. Announces Resignation of Briggs Morrison from the Board of Directors, Effective April 1, 2021

The Schall Law Firm Announces the Filing of A Class Action Lawsuit Against Nextcure, Inc

New 90-day high: €10.30

NextCure, Inc. Announces the Appointment of Han Myint as Chief Medical Officer

NextCure, Inc. Provides Updates on NC318 Clinical Program

New 90-day high: €10.10

Rosen Reminds Nextcure, Inc. Investors of Important November 20 Deadline in Securities Class Action

Revenue in line with expectations

Bernstein Liebhard Reminds Investors of the Deadline to File Lead Plaintiff Motion in Securities Class Action Lawsuit Against Nextcure Inc

Block & Leviton LLP Reminds Investors of Nextcure, Inc. for Violations of the Federal Securities Laws

New 90-day low: €7.25

Nextcure, Inc. Announces Resignation of Kevin N. Heller from Chief Medical Officer

Scott+Scott Attorneys At Law LLP Files Securities Class Action Against NextCure Inc

New 90-day low - €7.65

First half earnings released

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Value Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from Russell Microcap Index

NextCure, Inc.(NasdaqGS:NXTC) dropped from S&P Biotechnology Select Industry Index

Hissedar Getirileri

Fiyat Oynaklığı

Şirket Hakkında

NextCure, Inc. Temel Bilgiler Özeti

0.0x

-0.7x

Kazanç ve Gelir